Back to Journals » OncoTargets and Therapy » Volume 9

Long-term gene therapy with Del1 fragment using nonviral vectors in mice with explanted tumors

Authors Kitano H, Mamiya A, Ishikawa T, Egoshi K, Kokubun S, Hidai C

Received 19 June 2015

Accepted for publication 30 November 2015

Published 25 January 2016 Volume 2016:9 Pages 503—516

DOI https://doi.org/10.2147/OTT.S90801

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Ram Prasad

Peer reviewer comments 3

Editor who approved publication: Dr Faris Farassati


Supplementary video supplied by Kitano H, Mamiya A, Ishikawa T, et al.

Views: 51

Hisataka Kitano,1 Atsushi Mamiya,1 Tomomi Ishikawa,2 Kayo Egoshi,3 Shinichiro Kokubun,2 Chiaki Hidai2

1Division of Dental Surgery, School of Medicine, Nihon University, Tokyo, Japan; 2Division of Physiology, Department of Biomedical Science, School of Medicine, Nihon University, Tokyo, Japan; 3School of Medicine, Nihon University, Tokyo, Japan

Abstract: Cancer gene therapy using nonviral vectors is useful for long periods of treatment because such vectors are both safe and inexpensive, and thus can be used repeatedly. It has been reported that gene therapy with an E3C1 fragment of Del1 in a mouse explanted tumor model improved prognosis. The present study aimed to analyze the long-term effects of repeated nonviral gene transfer of E3C1. Mice with explanted tumors of SCCKN cells, a human squamous carcinoma, were treated with a plasmid encoding E3C1. Plasmids were injected locally every week using a transfection reagent. Control mice treated with mock DNA started to be euthanized on day 18, because the tumors had grown to over 15% of the body weight, and all of them had died by day 43. On the other hand, the tumors in two of ten mice treated with E3C1 had disappeared. The other eight mice started to be euthanized on day 46 and eight of ten mice had been euthanized by day 197. After 18 days of therapy, the tumor volume of control mice was 2,804±829 mm3 and that of the E3C1 mice was 197±159 mm3. Histochemical studies showed enhanced apoptosis in the E3C1-treated tumors, as compared with controls. Changes in cell morphology and decreased polymerized actin induced by E3C1 indicated disturbed cell adhesion to the matrix. In in vitro studies of SCCKN cells, prolonged administration of an E3C1 recombinant protein to cultured cells reduced adhesion-independent growth of cancer cells, as compared with control cells. These data suggest that E3C1 treatment induces anoikis.

Keywords: cancer gene therapy, nonviral vector, apoptosis, anoikis, Del1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]